Cure8 research brief
Identifying people at very early, preclinical stages of Crohn’s disease could allow enrollment in prevention trials and earlier intervention. Faecal calprotectin may help select higher‑risk first‑degree relatives for further evaluation.
First‑degree relatives of Crohn’s patients, clinicians doing IBD screening or prevention research, pediatric gastroenterology teams, and researchers designing prevention trials.
The researchers screened FDRs aged 6–38 with faecal calprotectin; persistent elevation (>70 µg/g on at least two tests) triggered panenteric video capsule endoscopy or ileocolonoscopy.
About 19% of those screened had persistently elevated calprotectin; among evaluated participants, some had endoscopic findings compatible with presymptomatic Crohn’s disease and others had non‑specific mucosal changes or probable histological inflammation despite normal mucosa.
Higher calprotectin (>225 µg/g) was strongly predictive of presymptomatic disease in this cohort. The authors propose that calprotectin can help identify at‑risk individuals for prevention trials.
Findings are based on the study abstract (panenteric capsule/endoscopy and colonoscopy used after persistent calprotectin elevation). The predictive cutpoint (>225 µg/g) and prevalence estimates are cohort‑specific and need replication; the study does not provide results of any prevention intervention.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Competing interests: DT, SK, HH, WE, LP, YA-F, AMG, IA-B, OL, GF, WT and KC declare no conflicts in relation to the content of this study. KJ: Advisory board (AbbVie, McKesson Canada, Janssen, Viatris, Celltrion; CSL Behring Canada); Speaker’s bureau (AbbVie). JT: Research support from AbbVie and Johnson & Johnson; has received advisory board/speaker fees from Eli Lilly, AbbVie, Johnson & Johnson, Pfizer, Sandoz and Tillots Pharma. RP: Consultant for Abbott, AbbVie, Abbivax, Alimentiv, Amgen, AnaptysBio, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Inviva, Fresenius Kabi, Genentech, Gilead Sciences, Glaxo-Smith Kline, JAMP Bio, Janssen, Merck, Mirador, Novartis, Oppilan Pharma, Odyssey, Organon, Pandion Pharma, Pendopharm, Pfizer, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Roche, Sandoz, Sanofi, Satisfai Health, Shire, Sublimity Therapeutics, Spyre Therapeutics, Takeda Pharmaceuticals, Teva, Tillots, Trellus, Union Biopharma, Viatris, Ventyx, UCB; Speaker’s fees for AbbVie, Amgen, Arena Pharmaceuticals, Bristol-Myers Squibb, Celgene, Eli Lilly, Ferring, Fresenius Kabi, Gilead Sciences, Janssen, Merck, Organon, Pfizer, Roche, Sandoz, Shire, Takeda Pharmaceuticals; Advisory Boards for AbbVie, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Ferring, Fresenius Kabi, Genentech, Gilead Sciences, Glaxo-Smith Kline, JAMP Bio, Janssen, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Sandoz, Sanofi, Sublimity Therapeutics, Takeda Pharmaceuticals, Ventyx.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Measuring mucosal healing across the whole gut with stool markers, ultrasound, and capsule endoscopy may give a clearer picture of whether biologic treatment is working and help guide decisions about continuing or...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Capsule Endoscopy. The original article is from BMC Gastroenterology.
Noninvasive fecal calprotectin levels tracked with endoscopic disease activity in children with colonic Crohn's disease, suggesting FC could help reduce repeat endoscopies and better monitor treatment response.
